Fixed-duration ibrutinib-venetoclax for first-line treatment of patients with chronic lymphocytic leukemia: the REALITY-WW prospective real-world study cohortTalha Munir, Paolo Ghia, Ping Xu et al.|Future Oncology|2025Cited by 0
Real-world (RW) use of fixed-duration (FD) ibrutinib+venetoclax (Ibr+Ven) in patients (pts) with previously untreated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): Pooled analysis of REALITY-worldwide (WW) and REALITY-2 prospective cohort studiesCatherine Thiéblemont, Paolo Ghia, Emmanuelle Tchernonog et al.|Blood|2025Cited by 0